Showing 1 posts of 1 posts found.
Pfizer has revealed new Phase 2 data on its 20-valent pneumococcal conjugate vaccine candidate, known as PF-06482077 (20vPnC), detailing the …
Qureight paper argues for fibrosis extent as imaging biomarker in lung disease trials
START and Rome cancer institute partner to expand early-phase trial access in Italy
AbbVie expands Oxford R&D facility with new £120m UK research commitment
MedPharm appoints Jason Mieding as chief operating officer
UKRI backs five hubs developing AI tools for earlier disease detection